Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Not listed Phase 1 Interventional

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

NCT00016055
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
lymphokine-activated killer cells, temozolomide
Biological · Drug
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 23, 2026, 8:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Patient Portal Messaging Before Mailing Fecal Immunochemical Testing Kit on Colorectal Cancer Screening Rates

NCT05115916
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms, Colorectal Cancer Screening
Interventions
MyChart Priming Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
51 Years to 75 Years
Enrollment
3,880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 23, 2026, 8:42 AM EDT
Withdrawn Not applicable Interventional

Shared Decision Making for PTSD in Primary Care

NCT04504149
View directory record Official record
Conditions
PTSD
Interventions
Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 23, 2026, 8:42 AM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)

NCT04281784
View directory record Official record
Conditions
Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure，Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions
EHR-based Clinician Jumpstart
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2,512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 8:42 AM EDT
Not yet recruiting Early Phase 1 Interventional

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07727668
View directory record Official record
Conditions
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions
Iberdomide, CAR-T Leukapheresis, CAR-T Infusion
Drug · Procedure
Lead sponsor
Shambavi Richard
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

NCT04373031
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pembrolizumab, IRX 2
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Recruiting Phase 1 Interventional

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

NCT03219450
View directory record Official record
Conditions
Lymphocytic Leukemia
Interventions
NeoVax, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 8:42 AM EDT
Active, not recruiting Phase 2 Interventional

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Intra Uterine Device Insertion in Nulliparous Women

NCT01422226
View directory record Official record
Conditions
Contraception
Interventions
Misoprostol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 23, 2026, 8:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

NCT05660408
View directory record Official record
Conditions
Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma
Interventions
pp65 RNA LP (DP1), pp65/tumor mRNA RNA-LP (DP2), Surgical Biopsy/Resection
Biological · Procedure
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 39 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Recruiting Not applicable Interventional

Treating Complex Grammar Knowledge Deficits in School-Age Children With Developmental Language Disorder

NCT06911138
View directory record Official record
Conditions
Developmental Language Disorders
Interventions
Behavorial
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
8 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Tucson, Arizona • Athens, Ohio • Logan, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 8:42 AM EDT
Active, not recruiting Phase 2 Interventional

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

NCT04543071
View directory record Official record
Conditions
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
Interventions
Motixafortide, Cemiplimab, Gemcitabine, Nab paclitaxel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

NCT05846516
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
VSV-GP154, ATP150, ATP152, Ezabenlimab, ATP162
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Withdrawn Phase 2 Interventional

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

NCT06180863
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
oral azacitidine (CC-486)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 23, 2026, 8:42 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055
View directory record Official record
Conditions
Cancer
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 23, 2026, 8:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

NCT00390884
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Fluzone®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Months to 14 Months
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
5
States / cities
Layton, Utah • Pleasant Grove, Utah • Provo, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 23, 2026, 8:42 AM EDT
Terminated Phase 1 Interventional

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

NCT04328714
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Drug
Lead sponsor
Edwin Horwitz
Other
Eligibility
1 Year and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

NCT07150806
View directory record Official record
Conditions
Recurrent Meningioma
Interventions
Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography, Echocardiography Test, Gallium Ga 68-DOTATATE, L-lysine/L-arginine-containing Amino Acid, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Somatostatin Receptor Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
Joshua Palmer
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Terminated Not applicable Interventional

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

NCT00253552
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Sarcoma
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 24 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 23, 2026, 8:42 AM EDT
Active, not recruiting Phase 2 Interventional

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

NCT05638698
View directory record Official record
Conditions
Pancreas Cancer
Interventions
TG01 Vaccine, QS-21, Balstilimab
Biological · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 23, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

NCT03497845
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 23, 2026, 8:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Monocyte Priming When Consuming a Western Diet

NCT05348395
View directory record Official record
Conditions
Heart Diseases
Interventions
Experimental diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 8:42 AM EDT
Terminated Not applicable Interventional

Treatment of Depression Using a Mobile Application in the Dominican Republic

NCT04948996
View directory record Official record
Conditions
Depression Mild, Depression Moderate
Interventions
El Buen Consejo Móvil- Group (EBCM-G), El Buen Consejo Móvil- Individual (EBCM-I)
Behavioral
Lead sponsor
Northern Illinois University
Other
Eligibility
18 Years to 110 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 23, 2026, 8:42 AM EDT